SAN FRANCISCO, May 16, 2023 (GLOBE NEWSWIRE) — Hagens Berman urges Chinook Therapeutics, Inc. (NASDAQ:KDNY) investors who suffered substantial losses to submit your losses now.
Visit: www.hbsslaw.com/investor-fraud/KDNY
Contact An Attorney Now: KDNY@hbsslaw.com
844-916-0895
Chinook Therapeutics, Inc. (KDNY) Investigation:
The investigation focuses on Chinook’s statements related to the commercial prospects for its lead product candidate (atrasentan), which is under development, to treat patients with kidney disease.
As recently as April 25, 2023, Chinook assured investors that “we believe that we have developed what we think is one of the leading pipelines targeting kidney disease […] that’s really led by our – our most advanced program, which is called atrasentan […] that we in-licensed from …
